BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 30655165)

  • 1. Interconnection between Metabolism and Cell Cycle in Cancer.
    Icard P; Fournel L; Wu Z; Alifano M; Lincet H
    Trends Biochem Sci; 2019 Jun; 44(6):490-501. PubMed ID: 30655165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs.
    Roskoski R
    Pharmacol Res; 2016 May; 107():249-275. PubMed ID: 26995305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs.
    Roskoski R
    Pharmacol Res; 2019 Jan; 139():471-488. PubMed ID: 30508677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the cell division cycle in cancer: CDK and cell cycle checkpoint kinase inhibitors.
    Collins I; Garrett MD
    Curr Opin Pharmacol; 2005 Aug; 5(4):366-73. PubMed ID: 15964238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An insight into the emerging role of cyclin-dependent kinase inhibitors as potential therapeutic agents for the treatment of advanced cancers.
    Chohan TA; Qayyum A; Rehman K; Tariq M; Akash MSH
    Biomed Pharmacother; 2018 Nov; 107():1326-1341. PubMed ID: 30257348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histone acetylation and the cell-cycle in cancer.
    Wang C; Fu M; Mani S; Wadler S; Senderowicz AM; Pestell RG
    Front Biosci; 2001 Apr; 6():D610-29. PubMed ID: 11282573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting Cyclin-Dependent Kinases and Cell Cycle Progression in Human Cancers.
    Santo L; Siu KT; Raje N
    Semin Oncol; 2015 Dec; 42(6):788-800. PubMed ID: 26615126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting cell cycle kinases for cancer therapy.
    de Cárcer G; Pérez de Castro I; Malumbres M
    Curr Med Chem; 2007; 14(9):969-85. PubMed ID: 17439397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pyruvate kinase: Function, regulation and role in cancer.
    Israelsen WJ; Vander Heiden MG
    Semin Cell Dev Biol; 2015 Jul; 43():43-51. PubMed ID: 26277545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucose and glutamine metabolism control by APC and SCF during the G1-to-S phase transition of the cell cycle.
    Estévez-García IO; Cordoba-Gonzalez V; Lara-Padilla E; Fuentes-Toledo A; Falfán-Valencia R; Campos-Rodríguez R; Abarca-Rojano E
    J Physiol Biochem; 2014 Jun; 70(2):569-81. PubMed ID: 24604252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cell cycle checkpoint control mechanisms that can be disrupted in cancer.
    Dash BC; El-Deiry WS
    Methods Mol Biol; 2004; 280():99-161. PubMed ID: 15187251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Molecular mechanisms controlling the cell cycle: fundamental aspects and implications for oncology].
    Viallard JF; Lacombe F; Belloc F; Pellegrin JL; Reiffers J
    Cancer Radiother; 2001 Apr; 5(2):109-29. PubMed ID: 11355576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitors of cell cycle kinases: recent advances and future prospects as cancer therapeutics.
    Stone A; Sutherland RL; Musgrove EA
    Crit Rev Oncog; 2012; 17(2):175-98. PubMed ID: 22471707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclins and related kinases in cancer cells.
    Malumbres M
    J BUON; 2007 Sep; 12 Suppl 1():S45-52. PubMed ID: 17935277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclin-dependent kinase regulation during G1 phase and cell cycle regulation by TGF-beta.
    Ravitz MJ; Wenner CE
    Adv Cancer Res; 1997; 71():165-207. PubMed ID: 9111866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TGF-beta1-induced cell cycle arrest in renal mesangial cells involves inhibition of cyclin E-cdk 2 activation and retinoblastoma protein phosphorylation.
    Schoecklmann HO; Rupprecht HD; Zauner I; Sterzel RB
    Kidney Int; 1997 Apr; 51(4):1228-36. PubMed ID: 9083291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cell cycle regulation after exposure to ionizing radiation].
    Teyssier F; Bay JO; Dionet C; Verrelle P
    Bull Cancer; 1999 Apr; 86(4):345-57. PubMed ID: 10341340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of roscovitine, a selective CDK inhibitor, on cancer cells: bi-functionality increases its therapeutic potential.
    Wesierska-Gadek J; Borza A; Komina O; Maurer M
    Acta Biochim Pol; 2009; 56(3):495-501. PubMed ID: 19724778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel potent pharmacological cyclin-dependent kinase inhibitors.
    Węsierska-Gądek J; Chamrád I; Kryštof V
    Future Med Chem; 2009 Dec; 1(9):1561-81. PubMed ID: 21425979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A cell cycle-regulated inhibitor of cyclin-dependent kinases.
    Hengst L; Dulic V; Slingerland JM; Lees E; Reed SI
    Proc Natl Acad Sci U S A; 1994 Jun; 91(12):5291-5. PubMed ID: 8202483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.